Senescent cancer-associated fibroblasts in pancreatic adenocarcinoma restrict CD8+ T cell activation and limit responsiveness to immunotherapy in mice

Benjamin Assouline, Rachel Kahn, Lutfi Hodali, Reba Condiotti, Yarden Engel, Ela Elyada, Tzlil Mordechai-Heyn, Jason R. Pitarresi, Dikla Atias, Eliana Steinberg, Tirza Bidany-Mizrahi, Esther Forkosh, Lior H. Katz, Ofra Benny, Talia Golan, Matan Hofree, Sheila A. Stewart, Karine A. Atlan, Gideon Zamir, Ben Z. StangerMichael Berger, Ittai Ben-Porath*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Senescent cells within tumors and their stroma exert complex pro- and anti-tumorigenic functions. However, the identities and traits of these cells, and the potential for improving cancer therapy through their targeting, remain poorly characterized. Here, we identify a senescent subset within previously-defined cancer-associated fibroblasts (CAFs) in pancreatic ductal adenocarcinomas (PDAC) and in premalignant lesions in mice and humans. Senescent CAFs isolated from mouse and humans expressed elevated levels of immune-regulatory genes. Depletion of senescent CAFs, either genetically or using the Bcl-2 inhibitor ABT-199 (venetoclax), increased the proportion of activated CD8+ T cells in mouse pancreatic carcinomas, whereas induction of CAF senescence had the opposite effect. Combining ABT-199 with an immune checkpoint therapy regimen significantly reduced mouse tumor burden. These results indicate that senescent CAFs in PDAC stroma limit the numbers of activated cytotoxic CD8+ T cells, and suggest that their targeted elimination through senolytic treatment may enhance immunotherapy.

Original languageEnglish
Article number6162
JournalNature Communications
Volume15
Issue number1
DOIs
StatePublished - Dec 2024

Funding

FundersFunder number
CreER
Hiba Mohalwes and Raghad Herbawi
Israel Science Foundation
Cancer Research Institute
Alex U. Soyka Program
Gassner Fund for Medical Research
Israel Cancer Research Fund
Teva Israeli Bioinnovators
Abisch-Frenkel Foundation
Kaye Einstein Scholarship
Israel Cancer Research Fund International Collaboration Program
Siteman Cancer CenterR01-CA-252225, K99-R00 CA252153, R01-CA-276512
U.S. Army Medical Research Acquisition ActivityBC181712
U.S. Army Medical Research Acquisition Activity
NIHCA217208, R01 AG059244
Broad Institute3755/21, 2621/18, 1923/22, 820/22
Broad Institute
Ministry of Science and Technology, Israel4062
Ministry of Science and Technology, Israel
Ministry of Health, State of Israel3-15017
Ministry of Health, State of Israel

    Fingerprint

    Dive into the research topics of 'Senescent cancer-associated fibroblasts in pancreatic adenocarcinoma restrict CD8+ T cell activation and limit responsiveness to immunotherapy in mice'. Together they form a unique fingerprint.

    Cite this